Health Care

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

Health Care Recent News

Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs

PacBio reaffirms 2025 revenue outlook and unveils cost-cutting measures as Vega system demand grows and Revio usage meets expectations.

Neogen Q3 Earnings Fall Short On Expectations, Cuts Guidance Amid Macro Headwinds And Tariff Concerns

Neogen Corporation reports lower-than-expected Q3 earnings, declines in revenue, and a CEO transition, lowering its full-year guidance for 2025.

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.

Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound

CMS finalizes 2026 Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Medicare Advantage Rates Expected To Climb Over 5% In 2026, Easing Pressure On Managed Care

CMS raises 2026 Medicare Advantage payments by 5.06%, exceeding projections and benefiting insurers focused on value-based care.

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no earlier than 2039.

Tilray Brands Reports Lower Cannabis Sales In Q3, Trims 2025 Revenue Outlook

Tilray Brands missed Q3 revenue expectations and lowered FY25 outlook, while beverage and wellness units posted year-over-year revenue increases.

Walgreens Boots Alliance Q2 Profit Falls 47.5%, Suspends Guidance On Pending Private Equity Deal

Walgreens reports Q2 revenue beat with strong pharmacy growth, but earnings fall amid weaker retail sales and U.S. Healthcare shifts.

CVS Health Appoints Former UPS And Pepsi Exec As Finance Chief, Stock Soars

CVS names Brian Newman CFO and Amy Compton-Phillips CMO as leadership shifts follow Q4 revenue growth and ongoing executive restructuring.

Health Insurers Surge After Medicare Agency Increases Payment Rates

Health insurer stocks are trading higher after the market close on Monday following a report indicating the Trump administration will increase payment rates for Medicare insurers.

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients

Amneal shares data showing Crexont improves sleep and motor symptoms in Parkinson's patients, with Phase 4 trial underway for further evaluation.